Cargando…
Glasgow Prognostic Score predicts chemotherapy‐triggered acute exacerbation‐interstitial lung disease in patients with non‐small cell lung cancer
BACKGROUND: Interstitial lung disease (ILD) in patients with non‐small cell lung cancer (NSCLC) worsens the prognosis for overall survival (OS) due to chemotherapy‐triggered acute exacerbation (AE)‐ILD. The Glasgow Prognostic Score (GPS), which is based on serum C‐reactive protein and albumin levels...
Autores principales: | Kikuchi, Ryota, Takoi, Hiroyuki, Tsuji, Takao, Nagatomo, Yoko, Tanaka, Akane, Kinoshita, Hayato, Ono, Mariko, Ishiwari, Mayuko, Toriyama, Kazutoshi, Kono, Yuta, Togashi, Yuki, Yamaguchi, Kazuhiro, Yoshimura, Akinobu, Abe, Shinji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919129/ https://www.ncbi.nlm.nih.gov/pubmed/33480111 http://dx.doi.org/10.1111/1759-7714.13792 |
Ejemplares similares
-
Glasgow prognostic score for prediction of chemotherapy‐triggered acute exacerbation interstitial lung disease in patients with small cell lung cancer
por: Kikuchi, Ryota, et al.
Publicado: (2021) -
Impact of sarcopenia on chemotherapy‐triggered exacerbation of interstitial lung disease in patients with non‐small cell lung cancer
por: Kikuchi, Ryota, et al.
Publicado: (2021) -
Early intervention of plasma exchange combined with intensive immunosuppressive treatment for anti-MDA-5 antibody–positive rapidly progressive interstitial pneumonia: Two case reports
por: Ishiwari, Mayuko, et al.
Publicado: (2021) -
Surfactant protein D: A useful biomarker for distinguishing COVID‐19 pneumonia from COVID‐19 pneumonia‐like diseases
por: Togashi, Yuki, et al.
Publicado: (2022) -
Polymyxin B haemoperfusion treatment for respiratory failure and hyperferritinaemia due to COVID‐19
por: Ishiwari, Mayuko, et al.
Publicado: (2020)